ImmuneCyte Inc. is a global, clinical-stage biopharmaceutical company engaged in the research and development of innovative cell and gene therapeutics, including the fourth generation chimeric antigen receptor (CAR)-T cell, CAR-NK cell, and mononuclear cell therapies, for the treatment of cancer and vascular diseases. With global coronavirus pandemic, ImmuneCyte is also developing a multitiered immunotherapies in the fight against Covid-19. Connect with us at www.immunecyte.com, on Facebook at www.facebook.com/ImmuneCyte and on Instagram @ImmuneCyte.